Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives $4.94 Consensus Target Price from Analysts

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have been given a consensus rating of “Hold” by the seven analysts that are presently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $4.94.

A number of brokerages recently issued reports on CARM. BTIG Research lowered shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 10th. EF Hutton Acquisition Co. I upgraded shares of Carisma Therapeutics to a “strong-buy” rating in a report on Wednesday, October 30th. HC Wainwright reissued a “neutral” rating on shares of Carisma Therapeutics in a report on Monday, December 16th. D. Boral Capital reaffirmed a “buy” rating and set a $12.00 price target on shares of Carisma Therapeutics in a research note on Monday, January 13th. Finally, Evercore ISI reiterated an “in-line” rating and issued a $0.70 price target (down from $4.00) on shares of Carisma Therapeutics in a research report on Wednesday, December 11th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CARM. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Carisma Therapeutics during the second quarter worth approximately $40,000. Wexford Capital LP lifted its position in Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after buying an additional 15,000 shares in the last quarter. Finally, Barclays PLC boosted its stake in shares of Carisma Therapeutics by 3,661,933.3% during the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after buying an additional 549,290 shares during the period. Hedge funds and other institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Stock Performance

Shares of CARM stock opened at $0.46 on Friday. Carisma Therapeutics has a 12-month low of $0.38 and a 12-month high of $2.77. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23. The firm has a market capitalization of $19.37 million, a price-to-earnings ratio of -0.30 and a beta of 1.56. The business has a 50 day simple moving average of $0.53 and a 200 day simple moving average of $0.84.

Carisma Therapeutics (NASDAQ:CARM) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.31). The company had revenue of $3.39 million during the quarter. Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. On average, equities research analysts anticipate that Carisma Therapeutics will post -1.32 EPS for the current year.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.